Cancer is the most common cause of death in China. The incidence and mortality rate remain high in lung, gastric, liver, esophageal and colorectal cancers. The five-year survival rate for all cancers in China is 30.9%, and is not optimistic compared to 66% in the United States. Lack of early diagnostics and effective treatment are key reasons for the difference. Early diagnosis of cancer brings better opportunities for disease intervention and improved prognosis. For patients diagnosed with colorectal, breast and prostate cancers at early stages, the five-year survival rate is as high as 90%.
There are a few biomarkers available for cancer detection, such as CA125 for ovarian cancer, CA19-9 for pancreatic cancer, and CEA for colon and prostate cancers. However, current biomarkers are lack of sensitivity and specificity for early detection. Novel biomarkers for early diagnosis are urgently needed.
The company will focus on lung, gastric, liver, colorectal and other high-risk cancers in China, integrate genomics, proteomics and metabolomics platforms, use bioinformatics and artificial intelligence to analyze and search for tumor-specific markers, and constantly develop cancer diagnostic products.